

Jeanne Conry
(IS4)



CURRICULUM VITAE

Jeanne Ann Conry, MD, PhD

President, The Environmental Health Leadership Foundation (EHLF)

Past President, The International Federation of Gynecology and Obstetrics

Past President, The American College of Obstetricians and Gynecologists

Past Chair California District IX ACOG

Executive Board Member:

P2i Preconception to Infancy and The Forum Institute

Retired OBGYN from Kaiser Permanente, Northern California

MD University of California, Davis, PhD University of Colorado, Boulder, BA California State

University, Chico

Fellow of the American College of Obstetricians and Gynecologists

Honorary Fellowship:

AOFOG, Canada, France, EBCOG, Germany, India, Ireland, Japan, Philippines, RCOG, Taiwan.

HONORED by:

The United States House of Representatives for accomplishments in women's health with a commendation into the Congressional Record, The Visionary Leadership Award from the University of California,

Environmental Protection Agency: The Pacific Southwest Region Children's Environmental Health Champion Award. Placer County California.

Preconception to Infancy (Preconception to Infancy)

Jeanne Ann Conry, MD, PHD

To invest in the health of the next generation we must see an investment in the health and well-being of women across their lifespan. It has been conventional wisdom that to improve children' s health, we must look at the first 1000 days. Preconception to Infancy (P2i) would argue that our investment must include more than 1300 days: enough time to improve the health of women so if and when a pregnancy is planned medical problems are addressed and optimized. The investment includes safe and respectful maternity care. Preconception to Infancy AMPLIFIES these important messages around the globe. However, P2i truly brings global awareness of the impact environmental factors can have on the health of women, on the fetus, and on our children. P2i starts with the risks women face by taking prenatal vitamins contaminated with lead, mercury and arsenic! P2i suggests that we can measure body burden to help women understand their contamination with environmental toxicants—and then change our behaviors to decrease impacts. The National Institute of Health suggests that 60% of respiratory disorders are environmental, and autism—once thought to be a genetic disorder has a strong environmental factor. OBGYNs can take the lead, protect patients and improve women and children' s health

Hisashi Masuyama

(IS5)



CURRICULUM VITAE

Hisashi Masuyama, MD, PhD

Professional Position

- Executive Board Member and Chairperson of Education Committee of Japan Society of Obstetrics and Gynecology, Congress President of the 77th Annual Congress of JSOG in 2025
- Professor and Chairperson, Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
- Vice director, Okayama University Hospital
- Director, Department of Obstetrics and Gynecology, and Perinatal Center, Okayama University Hospital

Education

1987 M.D., Okayama University School of Medicine
1995 Ph.D., Okayama University Graduate School

Experience

1995-1997 Postdoctoral Fellow, St. Louis University, St. Louis, Missouri.
1997 Instructor, Dept of OB/GYN, Okayama University Medical School.
2000-2001 Research fellow, Case Western Reserve University, Ohio, supported by the research program from the Ministry of Education, Culture, Sports, Science and Technology of Japan.
2006 Assistant professor, after return to Japan.
2008 Associate professor

Current Positions

2017- Chairperson and professor, Dept of OB/GYN, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
2019- Vice director, Okayama University Hospital.
23-25/05/2025 Congress president, the 77th Annual Congress of JSOG, Okayama, Japan.

Recent clinical and basic research

Maternal and fetal medicine, especially preeclampsia, glucose intolerance, and intergenerational health care.

Awards and Fellowships

1997 Young Investigator Award, 10th Workshop on Vitamin D, Strasbourg, France.
2001 Young Investigator Award, the Endocrine Society's 83rd Annual Meeting at Denver, USA.
2004 Yagi Award, Okayama University Medical Award (Hayashibara Award)
2005 Okayama Medical Association Award (Yuki Award)
2016 APSselect Award (The American Physiology Society)
2017 Outstanding reviewer award (Journal of Reproductive Immunology)

Perinatal care from the perspective of preventive medicine

Perinatal care is not only about pregnancy, delivery, and puerperium, but also includes elements of preventive medicine such as preventing pregnancy complications and the aggravation of underlying diseases, improving pregnancy prognosis, and even preventing future maternal diseases, and is a field that is related to women's lifelong health.

In recent years, the Ministry of Health, Labor, and Welfare of Japanese government has clearly stated that it will establish a preconception care to support health management during pregnancy, delivery and puerperium, and the importance of preventive medical intervention has been recognized. The frequency of thinness and obesity in young Japanese women is increasing, and it has been suggested that this is a risk factor for pregnancy complications such as gestational diabetes and hypertensive disorder of pregnancy. It is also becoming clear that pregnancy complications are related to the development of lifestyle-related diseases such as diabetes, hypertension, and dyslipidemia in middle-aged and elderly people.

Moreover, the deterioration of the intrauterine environment due to pregnancy complications in the mother leads to fetal overnutrition and overgrowth or malnutrition and growth retardation, both of which increase the child's risk of developing obesity and lifestyle-related diseases in the future.

We are required to expand our role to perinatal care from the perspective of maternal health management throughout a woman's life stages, as well as the impact on the healthcare of the next generation.

Wei-Chun Chang 張維君
(IS6)



CURRICULUM VITAE

Wei-Chun Chang

China Medical University and Hospital, Vice President of the Taiwan Association of Obstetrics and Gynecology, Taiwan

Professional Position

Professor of Obstetrics and Gynecology, School of Medicine, CMU at Taichung

Director, Section of Gynecology Oncology, Department OB/Gyn, CMUH

Vice President, Taiwan Association of Obstetrics and Gynecology

Education

2021.08- Professor, School of Medicine, CMU

2015.01- Director, Section of Gyn. Oncology, CMUH

2006.09-2009.06 Ph.D., Institute of Medicine, Chung-Shan Medical University, Taiwan

2001.09 EBM workshop, University of Durham, UK

1999.09-2001.06 M.H.A. Institute of Health Care Management, China Medical University, Taiwan

1993.01-1993.07 Gyn. Oncology fellow Lin-Ko Medical Center, Chang-Gung Memorial Hospital, Taiwan

1980.09-1987.06 M.D. School of Medicine, China Medical College, Taiwan

Faculty Appointments

2021.08- Professor, Obstetrics and Gynecology, School of Medicine, CMUH, Taichung

Editorial Boards

2016.10- Taiwanese Journal of Obstetrics & Gynecology

Targeting Lipid Metabolism for Chemosensitivity in Epithelial Ovarian Cancer-Updated

*We-Chun Chang MD, MHA, PhD;
CMU and Hospital, Taichung, Taiwan*

Lipid metabolism plays a significant role in the progression of epithelial ovarian cancer (EOC) by providing essential resources for tumor growth, survival, and metastasis. Understanding lipid metabolic alterations can lead to the development of novel therapeutic and biomarkers researches. EOC cells increase their lipid stores through enhanced uptake using lipoprotein receptors, e.g., LDLR, LRP8, or LSR. Our previous work demonstrated that LDLR expression affects cisplatin sensitivity in EOC subtypes. High LDLR levels are associated with reduced sensitivity to platinum-based therapies in endometrioid and clear-cell EOCs. In addition to the non-autonomous entry of lipid metabolites to EOC progression, our recent work also had described a critical lipid metabolite autonomously produced by EOC cells to reduce chemo-sensitivity. We found ether-linked phosphatidylethanolamine (PE O-) is the critical lipid metabolite that enhances chemo-insensitivity, promotes cell growth and migration, and affects patient prognosis in EOC patients. Its role in EOC progression highlights the importance of lipid metabolism in cancer therapy and prognosis. Based on the effort accumulated in the team, we' ve utilized the know-how gained during research to conducted translational researches. Bearing the nature of lipoprotein as natural nanoparticle, we' ve implemented a lipoprotein-mimicking nanoparticle drug as therapeutics. In this talk, we will also demonstrate the potentials of lipoprotein receptor targeting Lipid-Polymer Nanoparticle (LPN) drug in the EOC experimental model. In all, our work represents a systemic and comprehensive translational approach toward combating EOC.